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Abstract 
Colorectal cancer (CRC) is the third most common cancer and one of the main causes of cancer death entire the 
world. Environmental, dietary, and lifestyle factors including red meat consumption, cigarette smoking, alcohol intake 
and family history are the most important risk factors of CRC. Multiple pathways including inflammation, oxidative 
stress, and apoptosis are involved in its incidence and progression. Resveratrol, a polyphenolic compound, has differ-
ent pharmacologic functions including anti-inflammation, cancer prevention, lipid-lowering effect, and hypoglycemic 
effect. Many studies have proved that resveratrol might also represent a chemo preventive effect on CRC. Thus, the 
aim of the current review is to depict the role of resveratrol in treatment of CRC in a molecular manner.
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Background
Colorectal cancer (CRC) is the third most common can-
cer global [1]. Hepatic metastasis is the leading cause of 
mortality in this cancer [2]. CRC has caused about 0.69 
million deaths, and its mortality rate is still growing up. 
The international Cancer Statistic indicated that there are 
1.36 million new CRC cases annually entire the world [3]. 
In Western countries, particularly in the United States, 
there is a recent decrease in CRC incidence rate that is 
due to increased screening such as colonoscopy and fecal 
occult blood test [4]. Enhanced screening contributes to 
early detection and treatment of precancerous polyps [5, 
6] as in high-income countries, the disease prevalence 
has been stable because of increased screening [7]. CRC 
treatment still poses a clinical problem while 5-year sur-
vival rates are about 65% which depends on tumor situ-
ation, stage of tumor detection and therapy [8]. Secular 
trend studies suggested that lifestyle, dietary, and envi-
ronmental factors including red meat intake, cigarette 
smoking, and alcohol intake are the most important risk 
factors of CRC [5, 9]. In addition, several studies have 
shown that a family history of CRC elevated the disease 
risk. Based on the previous observations, present guide-
lines propose that people with a family history of this 
cancer should be screened for CRC earlier than those 
without one [10]. Recognition of new therapeutic strate-
gies may enhance the survival rate of patients with CRC 
[11].
Along to various therapies, utilization of natural com-
pounds has been appeared as new horizon in the treat-
ment of a variety of diseases such as cancer [12–14]. In 
this regards, several in  vitro and in  vivo investigations 
have shown that phytochemicals act potential antioxi-
dant, anti-inflammatory and anti-carcinogenic roles by 
modulating certain signaling pathways and molecu-
lar biomarkers to stop the incidence and progression 
of CRC [15]. Resveratrol (trans-3, 4′, 5-trihydroxystil-
bene) which derivates from the stilbene family of phe-
nolic compounds, exists in berries, pines and nuts, and 
particularly in red grapes skin [16]. This compound has 
different pharmacological functions including anti-
inflammation, cancer inhibition, lipid-lowering effect, 
and hypoglycemic effect. Resveratrol inhibits lipid per-
oxidation and aggregation of thrombocytes thus plays 
as an anti-oxidant, anti-inflammatory and vasodilation 
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[17, 18]. Recently, it was found that resveratrol insti-
gates autophagy in cancer cells [19]. Resveratrol has been 
exhibited to raise the release of various pro-inflammatory 
cytokines from immune cells, which finally promotes 
cytotoxicity against cancer [20]. This safe and multi-tar-
geted natural agent has been connected with suppression 
of survival and invasion of cancer cells [21].
Many studies have proved that resveratrol might also 
represent a chemo preventive effect on CRC. A recent 
in  vitro study demonstrated that resveratrol in combi-
nation with 5-fluorouracil (5-FU), a chemotherapeutic 
drug, increased the effects of 5-FU via its effects as an 
anti-metastasis drug on CRC. It was prominent that 5-FU 
resistant cells were more susceptible to resveratrol illus-
trating a potential therapeutic strategy for 5-FU resistant 
CRC [21]. Previous studies also reported that resveratrol 
increases the anti-cancer activities of the chemothera-
peutic agent, oxaliplatin, in cell culture model of CRC. 
Resveratrol can synergistically increase the effects of 
oxaliplatin in tumor cell growth suppression [22].
Given that resveratrol is not considered as primary 
therapy in the treatment of cancer [23]. Multiple lines 
evidence indicated that resveratrol could be employed 
as the secondary line of therapy and primary line cancer 
therapies alongside resveratrol show significant results 
[23, 24]. In this regards, a wide ranges of studies con-
firmed that resveratrol with radiotherapy approaches or 
chemotherapies could be provided a good therapeutic 
regimen in the treatment of cancer patients [24, 25].
Metabolic kinetic studies have exhibited that resvera-
trol have high clearance rate in circulation and low bioa-
vailability [26–28], thus its application for CRC inhibition 
has been highly disputed. Some studies have recom-
mended that the possible reason for low amount of res-
veratrol in the circulation is that resveratrol induces the 
phase II metabolic enzymes UGT and sulfotransferase 
as soon as possible to generate resveratrol glucuronides 
and resveratrol sulfates [29, 30]. A recent clinical trial has 
clarified that the level of three resveratrol sulfate conju-
gates was increased in patients with oral uptake of 0.5–
1.0 g resveratrol each day and the progression of tumor 
cells was remarkably inhibited in them, proposing that 
daily oral administration of 0.5–1.0  g resveratrol might 
act a potential role in CRC inhibition [31]. Thus, the aim 
of the current review is to depict the role of resveratrol in 
treatment of CRC in a molecular manner.
Resveratrol as an anti‑inflammatory agent in CRC 
Chronic inflammation is one of the main mechanisms 
which involved in colon cancer. Therefore, Anti-inflam-
matory compounds may be beneficial in treatment of 
CRC. Cytokines are quickly released by damaged tis-
sues and are stimulators of inflammatory response [32, 
33]. Very recently studies have indicated that exposure 
of intestinal cells to cytokines can mobilize inflammatory 
pathways such as MAPKs, JAK-STAT and NF-kB cas-
cades, raise the expression of pro-inflammatory enzymes, 
induce the generation of pro-inflammatory mediators 
and also production of reactive oxygen species (ROS) [34, 
35]. Resveratrol decreases pro-inflammatory mediators, 
such as TNF-α and IL-1β, pro-inflammatory enzymes 
such as iNOS and COX-2 and inflammatory signaling 
pathways such as NF-kB (Fig. 1) [36].
Cancer cell metastasis and invasion are interconnected 
processes which involve cell proliferation, cell adhesion, 
cell migration, and proteolytic degeneration of tissue 
barriers such as the ECM and basal membrane. Multiple 
proteolytic enzymes which include matrix metallopro-
teinase (MMPs; especially MMP-2 and MMP-9) [37, 38] 
and intracellular adhesion molecule (ICAM; especially 
ICAM-1), take part in the degeneration of these barriers 
[39, 40]. Some of studies in pancreatic, breast, lung, and 
colon cancers have exhibited over-expression of MMPs 
in virulent tissues compared with near normal tissues 
[41, 42]. Resveratrol diminished the migration and inva-
sion of lung cancer cells due to suppression of NF-κB 
activation and MMP-2 and MMP-9 expression [43]. Pre-
vious studies have demonstrated that resveratrol works 
as a multi-tasking factor and has anti-inflammatory and 
anti-cancer functions in CRC [44, 45]. Recent studies 
have proved that resveratrol inhibits NF-κB-dependent 
signaling mechanisms [15]. Various pro-inflammatory 
mediators that have been demonstrated to change the 
tumor microenvironment, including members of tumor 
necrosis factor (TNF)-superfamily, are modulated by 
NF-kB [9, 10]. TNF-α which is generated in the tumor 
microenvironment, modulates cancer cells, their sur-
rounding stromal cells and the ECM in multiple cancers 
and acts as an autocrine and paracrine growth factor [46, 
47]. Recent study reported that resveratrol suppressed 
the invasion and viability of CRC cells induced by TNF-α 
and TNF-β [8]. Another study reported that resveratrol 
inhibited TNF-β and TNF-α-enhanced survival in CRC 
cells by increasing apoptotic factors such as cleaved 
caspase-3 [48]. This study also showed that resveratrol 
decreased NF-κB activation, NF-κB-dependent carci-
nogenic gene products (MMP-9 and CXCR4) as well as 
EMT-related signaling factors including vimentin, slug, 
and E-cadherin in CRC cells. There is also some evi-
dence which showed that resveratrol can inhibit MMP-9 
and vascular endothelial growth factor (VEGF) signal-
ing pathways. Suppression of MMP-9 and VEGF by res-
veratrol prevents metastasis and angiogenesis [49, 50]. 
Nitric oxide (NO) is produced by three isozymes of NO 
synthase. One of these izosymes is iNOS which is induc-
ible by cytokines and pro-inflammatory mediators and 
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is calcium independent while other ones are calcium/
calmodulin dependent and constitutively produced 
[51]. In human and animal models of CRC, it has been 
indicated that the activation and expression of iNOS is 
increased suggesting the significant role of NO in colon 
tumorigenesis [52]. Several studies have also reported 
that resveratrol decreased iNOS expression in colon can-
cer cells however its main mechanism is still unclear [53]. 
Pterostilbene (trans-3, 5-dimethoxy-4′-hydroxystilbene), 
a structural analogue of resveratrol, exerts an anti-
inflammatory action for inhibition of colon carcinogen-
esis which inhibits p38 MAPK signaling pathway leading 
to induction of COX-2 and iNOS [35]. In addition, res-
veratrol is a profitable, nontoxic supplementation and 
alternative strategy to decrease colitis and strongly colon 
cancer related to colitis. Resveratrol remarkably develops 
inflammation score, decreases the amount of neutrophils 
in the mesenteric lymph nodes and lamina propria, and 
Fig. 1 Schematic representation in targeting different signaling pathways using resveratrol as a novel therapeutic strategy in the treatment of 
colorectal cancer
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regulates CD3(+) T cells that release TNF-α and IFN-γ. 
P53, a marker of inflammation, is also diminished by res-
veratrol [54].
Resveratrol inhibits oxidative stress in CRC 
At the moment, oxidative stress has been growing up 
assumed as a main enhancer to carcinogenesis [55]. Sev-
eral studies have been concentrated on chemo preventive 
exert of resveratrol as an antioxidant against aging, car-
diovascular diseases and cancer. The antioxidant activ-
ity of resveratrol is mainly associated with its ability in 
inhibition free radical production, lipid peroxidation, 
and modulation of antioxidant-associated enzymes [56]. 
One of the important antioxidant enzymes is manganese 
superoxide dismutase, which converts damaging free 
radical, superoxide, into molecular oxygen and hydro-
gen peroxide [49]. Resveratrol suppresses the expression 
of this enzyme and therefore contributes to ROS inhibi-
tion [56]. Resveratrol has already represented suppres-
sor effects on peroxynitrite-mediated proteins and lipids 
oxidation [57] via up-regulation of SOD [58], catalase 
(CAT), glutathione peroxidase (GPX) [59] and activation 
of the Sirt1/AMPK and Nrf2 pathways [60].
Two substantial signaling molecules, the replication 
factor STAT3 and the protein kinase AKT, have been 
reported to be over-expressed or activated in most types 
of human cancers, thus, it is now usually approved that 
both proteins exhibit reliable goals for new anti-tumor 
drug design [61, 62]. CRC cell lines were found to rep-
resent fundamental activation of survival raising proteins 
including AKT and STAT3. Resveratrol inhibits AKT and 
STAT3 proteins that are recognized to have oncogenic 
ability in CRC [63]. Wallerath et  al. [64] demonstrated 
that resveratrol might quickly enhance NO generation 
in cultured endothelial cells. At physiologic levels, NO, 
as an antioxidant, supports the gastrointestinal mucosa 
from injuries, prevents leukocyte sticking, and protects 
mucosal blood flow [65, 66].
Resveratrol decreases CRC cell survival
In carcinomas, it has been discovered that integrin-
mediated signaling through focal adhesion provides the 
cytoskeleton reorganization and supports tumor devel-
opment, invasion and metastasis [67]. Some studies 
have demonstrated that accumulation of Focal Adhe-
sion Kinase (FAK) with integrins and cytoskeletal pro-
teins in focal contacts causes elevated cell migration, as 
well as potential modulation of cell growth and survival 
[68, 69]. Also, in tumors, FAK has been exhibited to be 
involved in cell migration, survival, invasion and metas-
tasis, gene expression and tumor stem cell self-renewal 
[70]. Resveratrol suppresses proliferation and invasion 
of CRC cells via induction of Sirt1 activity, reduction of 
NF-κB-mediated inflammatory pathway and inhibition of 
focal adhesion kinase (FAK) activity, leading to decreased 
focal adhesion molecules and an elevation in apopto-
sis [71]. Additionally, resveratrol inhibited invasion and 
colony forming capacity, cell growth, the expression of 
β1-Integrin and FAK activation of cells in alginate cancer 
microenvironment. Resveratrol suppressed NF-kB acti-
vation and therefore, inhibited NF-κB-dependent gene 
end-products which are involved in apoptosis, metastasis 
and invasion [71].
One subgroup of transforming growth factor (TGF)-β 
superfamily, bone morphogenetic proteins (BMPs), acts 
important roles in the regulation of several key phases 
of embryonic development, growth, differentiation and 
apoptosis of different cells [72]. Recent evidence indi-
cated that BMPs take part in cancer progression, such 
as colon cancer [73]. BMP starts its signaling via phos-
phatidyl inositol 3-kinase (PI3K)/Akt pathway [74, 75]. 
P13K/Akt signaling acts a serious role in regulating cell 
survival and apoptosis [76] which has been detected 
over-activated in many tumors to decrease apoptosis and 
promote proliferation. The tumor inhibitor phosphatase 
and tensin homolog (PTEN) down-regulates PI3K/Akt 
signaling and is often inactivated by mutations in several 
cancer types. Resveratrol reduces the phosphorylation of 
Akt1/2/3 significantly in CRC cells [77].
Resveratrol also represented dose-dependent sup-
pression of Wnt signaling pathway, which is one of the 
important pathways in several serious diseases like can-
cer. Resveratrol decreases expression of Wnt target genes 
including cyclin D1 and conducting, and suppresses 
the development of Wnt-induced cells and Wnt-driven 
CRC cells [78]. Other studies reported that resveratrol 
decreases the expression of cyclins D1 and D2, which 
directly regulate cell cycle progression [79]. These mol-
ecules are usually induced throughout malignancy [80] 
and inhibited by anticancer phytochemicals [81]. Also, 
cell cycle arresting by resveratrol in a variety types of can-
cer cell lines is well recorded [82]. In addition, resveratrol 
suppresses the activities of various enzymes related to 
DNA replication and cell proliferation [83]; these collec-
tive effects could be the acceptable reason for the effects 
of resveratrol on modulation of the cell proliferation [84].
Clinical trials: resveratrol and colorectal cancer
Despite all documented anticancer features of resvera-
trol, the majority of the investigations were carried out in 
pre-clinical and cell-culture methods. Since there are dif-
ferences in metabolism profile and genetics of humans, 
and also because the potential properties of resveratrol in 
animal models cannot be supposed equal to humans, the 
physiological impacts of resveratrol were also studied in 
humans.
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The toxicity, metabolism, and pharmacokinetics of 
resveratrol have been evaluated in cancer patients and 
healthy subjects [85, 86]. Resveratrol is swiftly metabo-
lized, mostly into sulfate conjugates and glucuronide 
which are excreted through the urine. Due to the low 
bioavailability because of its extensive metabolism, high 
doses of resveratrol (up to 5  g/day) have been used by 
investigators. Mentioned researches have revealed that 
this polyphenolic compound seems to be safe and well-
tolerated. However, adverse effects such as abdominal 
pain nausea and diarrhea, were seen in individuals con-
sume more than 1 g resveratrol daily [86]. Thus, clinical 
trials are studying this dose limitation [86, 87]. The poor 
bioavailability of resveratrol is an important problem 
regarding extrapolation of its impacts to humans, and 
different methods have been developed to increase its 
bioavailability, such as taking it with different foods, uti-
lizing it in combination with an additional phytochemical 
piperine, as well as using a nanotechnological formula-
tions, micronized powders, or prodrug approach [88–
93]. Table 1 shows the list of clinical trials on resveratrol 
and various cancers, including CRC.
An investigation conducted on the pathogenesis of 
prostate cancer revealed that resveratrol is able to delay 
cancer recurrence. Approximately 33–50% of patients 
with prostate cancer experience biochemical disease 
recurrence after primary therapy. Increasing concentra-
tion of prostate-specific antigen (PSA) is the earliest dis-
ease recurrence indication. MPX, pulverized muscadine 
grape skin containing resveratrol, delayed recurrence 
development by prolongation of the PSA doubling time 
(PSADT) by 5.3  months. However, these findings were 
not significant [94]. This investigation is carrying on in 
phase II clinical trial, so it remains to be observed if MPX 
is a viable option of therapy. Conflictingly, a second clini-
cal trial implicating resveratrol and prostate cancer cer-
tainly concluded that it would not be a viable therapy. 
Despite pre-clinical data that resveratrol regulates the 
activity of androgen receptor and decreases androgen 
generation, Kjaer et  al. [95] indicated that, since it had 
no impact on PSA levels or prostate volume, resveratrol 
could not treat prostate cancer. Based on what discussed, 
it seems improbable that resveratrol will demonstrate to 
be efficient for prostate cancer therapy, but further clini-
cal trials require to be done to confirm this.
There are other researches that show resveratrol as 
a tenuous therapy, including in certain multiple mye-
loma (MM) types. Resveratrol was observed to suppress 
STAT3, AKT, and NF-κB as well as exerts cytotoxic 
effects in MM cell lines [96]. SRT501 was examined in 
subjects with refractory or relapsed MM. Despite con-
vincing evidence of pre-clinical studies that resveratrol 
contributes to the therapy of MM patients, the clini-
cal trial showed that it caused numerous severe adverse 
effects, the most prominent of which was renal failure 
[97]. Since SRT501 had no nephrotoxic effects in a phase 
I trial, and it was documented to be safe in a phase II 
study for patients with colorectal cancer, this adverse 
effects seemed to be MM-specific. These findings show 
that SRT501 and probably any other resveratrol versions 
could not be a potential therapy for MM.
Likewise, in clinical trials performed in colorectal 
cancer patients, the findings seem hopeful, but remain 
indeterminate regarding whether resveratrol could be 
an appropriate therapy. It has been revealed that res-
veratrol suppresses tumor growth and triggers apoptosis 
in human colon cells in  vitro, and murine models indi-
cated that resveratrol suppresses colorectal carcino-
genesis and inflammation [98, 99]. Thus, two clinical 
trials aimed to distinguish resveratrol pharmacokinet-
ics in hepatic metastases or colorectal tissue. After a 
2-week resveratrol or SRT501 therapy, in the colorec-
tal cancer tissues of patients, the measured parent res-
veratrol as well as its main metabolites levels were alike 
Table 1 Clinical trials studies on resveratrol and cancer
CRC colorectal cancer, PC prostate cancer, MM multiple myeloma, BC breast cancer
Cancer Dose of resveratrol Duration of study Number 
of patient
Outcome Refs
CRC 5 g/day 14 days 6 Increase the cleaved caspase-3 in malignant hepatic tissue. [88]
0.5 or 1 g/day 8 days 20 Decrease expression of Ki-67 [31]
20 or 80 mg/day 2 weeks 8 Inhibit the Wnt pathway [100]
PC 150 mg or 1000 mg/day 4 months 66 Decrease the serum levels of androgens with no alterations in prostate 
tumor growth
[95]
4000 mg/day 14 Safe [94]
MM 5 g/day 21 days 24 Unacceptable safety profile and minimal efficacy in patients with relapsed/
refractory multiple myeloma highlighting the risks of novel drug devel-
opment in such populations
[97]
BC 5 or 50 mg twice a day 3 months 39 Reduce the methylation of RASSF-1α [101]
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to the effective resveratrol levels utilized in preclinical 
investigations. However, the anticancer function of the 
metabolites of resveratrol has yet to be validated, hence it 
is obscure whether this result provides additional vindi-
cation for pursuing resveratrol as a potential therapy for 
colon cancer. Furthermore, caspase-3 levels, an apoptotic 
biomarker, and Ki-67 levels, a biomarker of prolifera-
tion, were slightly influenced in tissue samples [31, 88]. 
Although it is proven that resveratrol possesses some 
pharmacological effects, it is obscure if these effects are 
considerable enough to make it a beneficial therapeutic 
material for colon cancer treatment.
Conclusions
CRC is a prevalent cancer and one of the main causes 
of cancer mortality entire the world. Several factors 
from genetics to diet are involved in the incidence of 
this malignancy. Its pathophysiology is heterogeneous 
which multiple molecules and various signaling pathways 
including inflammation, oxidative stress, and apoptosis 
are implicated in its incidence and progression. A num-
ber studies have supported the potential effects of res-
veratrol in CRC treatment. This polyphenol compound 
represents different properties including antioxidant, 
anti-inflammatory, apoptosis inducer, and anti-angiogen-
esis efficacy. Due to these significant effects, resveratrol is 
suggested as a novel therapeutic agent for cancers. More-
over, some studies reported that consumption of res-
veratrol in combination with other anti-cancer drugs can 
increase their effects and also decrease their side effects. 
Thus, this multi-tasking compound can be a new candi-
date in CRC treatment however, more human studies are 
needed.
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